Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.
Read time: 1 mins
Last updated:4th Feb 2013
The primary objective of this clinical trial in patients suffering from hay fever is the assessment of the safety and clinical tolerability of increasing doses of gpASIT+TM when administered by subcutaneous injections, in order to determine the maximal tolerated dose.
|Study start date||2013-02-04|